Last reviewed · How we verify
NCT03813823
Biobehavioral Correlates of Acute Phobic Fear
trial testing Fear tasks in Phobia in 30 participants. Status unknown.
1 August 2019
Quick facts
| Lead sponsor | University of Colorado, Boulder |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 4 February 2019 |
| Primary completion | 1 August 2019 |
| Estimated completion | 1 August 2019 |
Drugs / interventions tested
- Fear tasks
Conditions studied
- Phobia — all drugs for Phobia →
Sponsor
University of Colorado, Boulder
Who can join
Adults 18 to 40, any sex, with Phobia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study seeks to measure the time course of circulating proinflammatory markers (interleukin-1 beta \[IL-1β\], interleukin-6 \[IL-6\], tumor necrosis factor alpha \[TNF-α\], and C-reactive protein \[CRP\]) and salivary alpha amylase (sAA) following laboratory fear arousal. Further, this study seeks to implement neurocognitive, physiological, and self-report measures to explore the role of threat sensitivity as a predictor of this response. The broad research question seeks to better understand the relationship between neurocognitive fear and subsequent stress responding elicited by both the immune system (i.e., proinflammatory markers) and autonomic nervous system (i.e., sAA). In light of these aims, the primary outcomes of the current study are the proinflammatory markers (IL-1β, IL-6, TNF-α, CRP), while secondary outcomes consist of sAA, neurocognitive measures (i.e., dot-probe task), physiological correlates (i.e., heart rate, galvanic skin response), and self-report measures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03813823
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Phobia
Currently open trials in the same condition.
- NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
- NCT06420557 — Unconscious Reduction of Fear Through Decoded Neuro-Reinforcement · NA · recruiting
Other University of Colorado, Boulder trials
Trials by the same sponsor.
- NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
- NCT07011160 — Neural Substrates Underlying Adaptations in Manual Dexterity of Older Adults · NA · not yet recruiting
- NCT07127965 — Exercise Adherence and Cognitive Decline: Phase 2 · NA · recruiting
- NCT06588582 — Perceptual Influences From Smoking Cannabis: an Experimental Study · NA · recruiting
- NCT06769022 — Exercise Adherence and Cognitive Decline · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03813823 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Boulder
- Last refreshed: 23 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03813823.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing